(Q35048548)

6 August 2017

title

Updated UK Recommendations for HER2 assessment in breast cancer (English)

1 reference

6 August 2017

8

Andrew Hanby

1 reference

6 August 2017

Emad A Rakha

1

0 references

Ian Ellis

object named as

Ian O Ellis

11

0 references

Sarah E. Pinder

2

object named as

Sarah E Pinder

1 reference

6 August 2017

7

Elena Provenzano

1 reference

6 August 2017

4

Merdol Ibrahim

1 reference

6 August 2017

John M S Bartlett

3

1 reference

6 August 2017

Jane Starczynski

5

1 reference

6 August 2017

Pauline J Carder

6

1 reference

6 August 2017

Sally Hales

9

1 reference

6 August 2017

Andrew H S Lee

10

1 reference

6 August 2017

National Coordinating Committee for Breast Pathology

12

1 reference

6 August 2017

language of work or name

English

0 references

publication date

8 December 2014

1 reference

Journal of Clinical Pathology

6 August 2017

published in

1 reference

6 August 2017

volume

68

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

93-99

1 reference

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

HER2 testing in the UK: further update to recommendations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Best Practice No 176: Updated recommendations for HER2 testing in the UK

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

HER-2/neu (c-erb-B2) gene and protein in breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

8 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

2 references

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316916

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

25 October 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: experience from a tertiary care centre in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

HER-2/neu analysis in breast cancer bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202571

HER2 genetic heterogeneity in breast carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25488926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25488926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25488926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/JCLINPATH-2014-202571

1 reference

6 August 2017

1 reference

6 August 2017

1 reference